CBD makers can no longer require the fantasy that their products are exempt from the Controlled Substance Act. De-scheduling cannabis is the fix.
After hovering on the sidelines for many decades while CBD ecommerce state outlines, America’s federal drug police have announced new guidelines which may portend a crackdown on CBD oil products — be they single chemical formulas or entire plant extracts derived from low-resin industrial hemp or high-resin cannabis.

Many CBD hemp oil entrepreneurs appeared caught off guard. Apparently they believed the fantasy that cannabidiol was lawful in all fifty states, a misperception encouraged by numerous online companies.
Project CBD has been debunking the claim that CBD is legal for the previous seven decades. We assert that CBD’s illegality must be vociferously contested. We strongly support how much cbd oil for anxiety the legalization of all forms of cannabis — industrial hemp, as well as marijuana — and all elements of this plant, including CBD and THC.

But Project CBD hasn’t felt that sticking ‘s head in the sand and pretending something is lawful is the very best method to challenge an unjust law. If one subscribed to the mistaken belief that CBD is lawful, then why invent a coherent approach to modify the law? Now it seems that the ostriches are coming home to roost.
Unfortunately, some CBD hemp oil companies, in their quest for quick profits and market share, have been all too willing to denigrate cannabis (it gets you high — horrors!) And throw the entire plant under the bus. CBD has frequently been misportrayed as the truly medical part of the plant, while THC has been forged as marijuana’s regrettable recreational component. It’s all malarkey.

THC has amazing health properties, which augment and magnify CBD’s formidable healing potential. In other words, THC and CBD are the power few cannabis therapeutics; they work best together as part of a whole plant arrangement. Medical patients must have access to a vast assortment of cannabis-based remedies, not just low-THC or no-THC choices.
The "CBD-only" strategy has failed. Legalizing entire plant cannabis ought to be the target — not just 1 portion of this plant.

Voice your support for cannabis medicine by insisting the ENTIRE plant, and each of its components, be de-scheduled. Our colleagues at Patients Out of Time have launched a request to de-schedule cannabis. Sign it and pass it around far and wide!
As it stands, single-molecule THC (Marinol) is currently a lawfully prescribed medication in all fifty states, and soon CBD are also approved as a lawful single-molecule pharmaceutical. But entire plant CBD-rich and THC-rich cannabis will remain federally illegal for the foreseeable future.

This ‘s ridiculous — and it’s a terrible situation for millions of people who might benefit from cannabis therapeutics.
It’s unclear to what extent that the DEA will follow through on its threat to maneuver against companies that manufacture cannabis oil solutions. For the moment, it might seem that cannabis oil companies which operate in compliance with state medical marijuana laws will stand a better prospect of withstanding a federal assault — at least initially.

The Rohrbacher Amendment, which must be renewed by Congress from April 2017, specifically prohibits the Justice Department from using federal funding to undermine state medical marijuana laws.
To reiterate: In the United States, CBD is categorized as a Schedule 1 Drug, if derived from industrial hemp or marijuana. This has always been the case because the passing of the Controlled Substances Act in 1970. The 2014 Farm Bill defined industrial hemp as different from marijuana (any cannabis with 0.3 percent THC or less would be considered hemp as opposed to marijuana). But the Farm Bill did not really legalize industrial hemp. It did, but split a temporary exemption from the Controlled Substances Act for certified hemp farmers and producers in states which have legalized industrial hemp with the proviso that their efforts have to be linked to a state university research program.

The pretzel logicians in the DEA recently issued a three-page "clarifying" record on cannabis oil products, including CBD-rich extracts, entitled "Establishment of a New Drug Code for Marihuana Extract. " The document claims: "The DEA has established separate code amounts for marihuana and also for tetrahydrocannabinols, although not for marihuana infusion. To better track these substances and comply with treaty provisions, DEA is creating a separate code number for marihuana extract with another definition: ‘Meaning an infusion containing one or more cannabinoids that’s been derived from any plant of the genus Cannabis, other than the split resin (whether crude or purified) obtained from the plant.
This so-called clarification follows the FDA’s assertion that it has not approved CBD as a dietary or supplement. All of cannabinoids, whether or not not, are all scheduled. Here is the FDA’s policy statement on CBD:
Can products which contain cannabidiol be marketed as dietary supplements?

No. Based on available evidence, FDA has concluded that cannabidiol products are excluded from the dietary supplement definition under section 201(ff)(3)(B)(ii) of their FD&C Act. Under that provision, if a chemical (such as cannabidiol) has been approved for investigation as a new drug for which substantial clinical investigations have been instituted and for which the existence of such investigations has been made public, then products containing that chemical is outside the definition of a dietary supplement. FDA believes a chemical to be "authorized for investigation as a new drug" whether it is the subject of an Investigational New Drug application (IND) which has gone into effect.
There’s an exception to section 201(ff)(3)(B)(ii) if the substance was "marketed as" a dietary supplement or as a traditional food before the new drug investigations were approved.

However, based on available evidence, FDA has concluded that this isn’t true for cannabidiol. For more information on this provision, including an explanation of this phrase "marketed as," see Draft Guidance for Industry: Dietary Supplements: New Dietary Ingredient Notifications and Related Issues.
The FDA isn’t aware of any evidence that could call into question its existing conclusion that cannabidiol products are excluded from the dietary supplement definition under section 201(ff)(3)(B)(ii) of their FD&C Act.

Interested parties can present the agency with any proof that they think has bearing on this particular issue.
Is it lawful, in interstate commerce, to market food to which cannabidiol has been added?
No. Under section 301 (a) of this FD&C Act, it is illegal to introduce or deliver for introduction into interstate commerce any food (including any animal food or feed) to which has been added a drug for which substantial clinical investigations have been instituted and for which the existence of such investigations has been made public. There are exceptions, including when the drug was marketed in food before any substantial clinical investigations involving the drug was instituted or, in the event of animal feed, the drug is a brand new animal drug approved for use in feed and utilized in accordance with the approved labeling.

However, based on available evidence, FDA has concluded that none of them is true for cannabidiol. FDA has therefore concluded it is a prohibited act to introduce or deliver for introduction into interstate commerce any food (including any animal food or feed) to which cannabidiol has been added. FDA isn’t aware of any evidence that could call into question this conclusion.

Interested parties can present the agency with any proof that they think has bearing on this particular issue.